FDA Draft Guidance Outlines BLA Path for Individualized Gene Editing

FDA issued a new draft guidance on October 27, 2026, outlining how sponsors can structure and maintain a single biologics license application (BLA) for individualized genome editing (GE) products tailored to each patient's genetic variant.¹^,² The document, Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, was issued by the Center for Biologics Evaluation and Research (CBER).² The Centers for Medicare & Medicaid Services (CMS) announced the same day that it will expand its Cell and Gene Therapy (CGT) Access Model beyond sickle cell disease.¹

"By providing a clear and scientifically rigorous framework for BLA submission and postapproval management, we are helping to ensure that patients—including those with ultra-rare conditions for whom no treatment currently exists—can more efficiently access therapies that may be life-changing," said Karim Mikhail, BPharm, MS, director of CBER, in an agency press release.¹

What does the draft guidance propose?

Some rare diseases are caused by mutations that differ from patient to patient, so a single product cannot treat everyone with the same condition.¹ The guidance addresses how a BLA can accommodate multiple patient-specific product variants and how sponsors can add new variants after approval.¹

Central to the framework is the Individualized Feature Space (IFS), a set of predefined boundaries describing how a GE product may vary while remaining within the scope of a single BLA.¹ According to the guidance, the IFS covers the allowable range of a product's variable features, such as guide RNA spacer sequences or editor proteins.² A new variant may fall within those boundaries and show adequate safety and activity in assays. If so, sponsors can add it to the BLA without additional clinical trials, relying on the trials that supported approval plus in vitro data for the new variant.¹

"For patients, new product variants can reach them faster, even if the product variant hasn't been evaluated in a clinical trial. And this helps to ensure that individuals with ultra-rare or even unique gene variants are not left behind," said Andrew Byrnes, PhD, director of the Division of Gene Therapy 1 in CBER's Office of Gene Therapy CMC, in an FDA webinar.³

The guidance also covers manufacturing, safety testing, including risks of unintended genetic changes, and product naming and labeling.¹ FDA said in the release that the guidance puts into practice key elements of its Rare Disease Framework.¹

How is CMS expanding access to these therapies?

Through the voluntary CGT Access Model, CMS negotiates outcomes-based agreements with manufacturers on behalf of state Medicaid programs.¹ The model initially focused on sickle cell gene therapies exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia).⁴ An August 2026 evaluation found that 34 state Medicaid agencies took part, covering roughly 84% of Medicaid beneficiaries with sickle cell disease.⁴

CMS said the evaluation found that CMS-led negotiations eased states' administrative burden and strengthened negotiating leverage by pooling beneficiaries.¹ The evaluation also noted that some agencies found participation requirements more complex and burdensome than anticipated.⁴ In the coming months, CMS will release a request for applications inviting manufacturers of therapies for other conditions to participate. It aims to start negotiations sooner after FDA approval or licensure.¹

What are the limitations?

The guidance is a draft and does not establish binding requirements. In addition, its recommendations may change after public review. The Federal Register notice was published on October 28, 2026, and comments to docket FDA-2026-D-11783 are due by November 27, 2026.⁵ It remains to be seen how FDA will define acceptable IFS boundaries and assay evidence for specific products. CMS has not released the request for applications or specified which conditions or therapies the expanded model will include. Outcomes-based agreements may add administrative complexity for states.⁴

References

1. US Department of Health and Human Services. FDA and CMS announce new steps to advance gene therapies and expand access for patients with rare diseases. Press release. Published October 27, 2026. Accessed October 29, 2026. https://www.hhs.gov/press-room/fda-cms-advance-gene-therapies-rare-diseases-patient-access.html
2. FDA. Individualized human genome editing products: considerations for BLA submission and postapproval management; draft guidance for industry. October 2026. Accessed October 29, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval
3. FDA. Individualized human genome editing products: considerations for BLA and postapproval management. YouTube. Published October 27, 2026. Accessed October 29, 2026. https://www.youtube.com/watch?v=8UnKO56ndbg
4. Abt Global. The Cell and Gene Therapy (CGT) Access Model: evaluation of CMS-led development of outcomes-based agreements. Centers for Medicare & Medicaid Services. August 13, 2026. Accessed October 29, 2026. https://www.cms.gov/priorities/innovation/data-and-reports/2026/cgt-first-eval-report
5. FDA. Individualized human genome editing products: considerations for BLA submission and postapproval management; draft guidance for industry; availability. Fed Regist. 2026;91:67838. Published October 28, 2026. Accessed October 29, 2026. https://www.federalregister.gov/documents/2026/10/28/2026-21954/individualized-human-genome-editing-products-considerations-for-bla-submission-and-postapproval